OraSure Technologies, Inc.

DB:EP3 Stock Report

Market Cap: €282.4m

OraSure Technologies Valuation

Is EP3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of EP3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate EP3's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate EP3's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for EP3?

Key metric: As EP3 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for EP3. This is calculated by dividing EP3's market cap by their current earnings.
What is EP3's PE Ratio?
PE Ratio25.1x
EarningsUS$11.37m
Market CapUS$291.66m

Price to Earnings Ratio vs Peers

How does EP3's PE Ratio compare to its peers?

The above table shows the PE ratio for EP3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25x
PHH2 Paul Hartmann
14xn/a€838.2m
SBS Stratec
43.3x25.1%€434.0m
PUS PULSION Medical Systems
27xn/a€136.0m
M12 M1 Kliniken
15.5x16.0%€259.8m
EP3 OraSure Technologies
25.1x-46.8%€291.7m

Price-To-Earnings vs Peers: EP3 is expensive based on its Price-To-Earnings Ratio (25.1x) compared to the peer average (25x).

Price to Earnings Ratio vs Industry

How does EP3's PE Ratio compare vs other companies in the European Medical Equipment Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
EP3 25.1xIndustry Avg. 32.7xNo. of Companies9PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: EP3 is good value based on its Price-To-Earnings Ratio (25.1x) compared to the European Medical Equipment industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is EP3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

EP3 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.1x
Fair PE Ratio6.4x

Price-To-Earnings vs Fair Ratio: EP3 is expensive based on its Price-To-Earnings Ratio (25.1x) compared to the estimated Fair Price-To-Earnings Ratio (6.4x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst EP3 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€3.72
€5.60
+50.6%
33.4%€8.77€3.90n/a4
Feb ’26€3.80
€5.60
+47.4%
33.4%€8.77€3.90n/a4
Jan ’26€3.42
€5.75
+68.1%
28.9%€8.63€4.79n/a4
Dec ’25€3.62
€5.56
+53.5%
28.9%€8.34€4.63n/a4
Nov ’25€3.70
€5.51
+48.9%
28.9%€8.27€4.59n/a4
Oct ’25€3.80
€5.42
+42.6%
28.9%€8.13€4.52n/a4
Sep ’25€4.06
€5.50
+35.4%
28.9%€8.24€4.58n/a4
Aug ’25€4.10
€5.62
+37.0%
28.5%€8.26€4.13n/a4
Jul ’25€3.94
€6.11
+55.0%
20.9%€8.30€5.07n/a4
Jun ’25€4.30
€6.11
+42.0%
20.9%€8.30€5.07n/a4
May ’25€5.00
€6.97
+39.3%
11.5%€8.30€6.00n/a5
Apr ’25€5.65
€7.06
+24.9%
10.0%€8.31€6.46n/a5
Mar ’25€6.50
€7.06
+8.6%
10.0%€8.31€6.46n/a5
Feb ’25€6.80
€6.76
-0.6%
22.0%€8.22€4.57€3.805
Jan ’25€7.45
€5.95
-20.2%
21.2%€8.36€4.65€3.425
Dec ’24€6.70
€5.60
-16.4%
10.5%€6.54€4.67€3.625
Nov ’24€4.82
€5.67
+17.7%
9.2%€6.56€4.92€3.705
Oct ’24€5.65
€5.43
-3.9%
12.6%€6.39€4.56€3.805
Sep ’24€5.90
€5.43
-8.0%
12.6%€6.39€4.56€4.065
Aug ’24€4.26
€5.47
+28.4%
15.3%€6.23€4.45€4.105
Jul ’24€4.60
€6.39
+38.9%
4.8%€6.90€5.98€3.945
Jun ’24€4.72
€6.39
+35.4%
4.8%€6.90€5.98€4.305
May ’24€6.00
€5.84
-2.6%
8.5%€6.41€5.04€5.004
Apr ’24€5.30
€5.50
+3.7%
11.1%€6.55€5.15€5.654
Mar ’24€5.90
€5.50
-6.8%
11.1%€6.55€5.15€6.504
Feb ’24€5.05
€5.17
+2.3%
16.7%€6.65€4.51€6.804
Analyst Price Target
Consensus Narrative from 4 Analysts
€5.60
Fair Value
33.6% undervalued intrinsic discount
4
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 03:36
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

OraSure Technologies, Inc. is covered by 17 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Charley JonesBarrington Research Associates, Inc.
Karen KoskiBTIG
Mark MassaroCanaccord Genuity